Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMkango Resources Regulatory News (MKA)

Share Price Information for Mkango Resources (MKA)

Share Price is delayed by 15 minutes
Get Live Data
39.50    -0.50 (-1.25%)
Bid:
39.00
Ask:
40.00
Spread: 1.00 (2.564%)
Market Cap: £153.10m
MKA Live PriceLast checked at - London Stock Exchange

Intraday Mkango Resources Share Chart

MKANGO PROVIDES UPDATE ON PLACING

16 Aug 2021 07:00

RNS Number : 6432I
Mkango Resources Limited
16 August 2021
 

 

 

 

 

 

MKANGO RESOURCES LTD.

550 Burrard Street

Suite 2900

Vancouver

BC V6C 0A3

Canada

 

 

MKANGO PROVIDES UPDATE ON PLACING

 

London / Vancouver: 16 August, 2021 - Mkango Resources Ltd. (AIM/TSX-V: MKA) (the "Company" or "Mkango") is pleased to announce that further to the Company's announcement of 5 August 2021, it has now received TSX-V conditional approval for the issuance of 23,007,495 common shares of no par value ("New Shares") at an issue price of £0.24 (approx. C$0.42) per New Share, raising £5.52 million (£5.29m net of fees) from new and existing investors (the "Placing").

Subscriptions from related parties, being Resource Early Stage Opportunities Company ("RESOC") for 1,666,666 New Shares and Derek Linfield for 2,916,666 New Shares, remain conditional on approval from shareholders other than RESOC (in respect of its subscription) and Mr Linfield (in respect of his subscription), which approval will be sought at the Company's Annual General and Special Meeting of Shareholders (the "Meeting") to be held on 6 October 2021. An investor who had previously indicated that it wished to delay its subscription for 350,000 New Shares until after the Meeting informed the Company earlier this week that it no longer wished to delay such subscription.

Accordingly, 18,424,163 New Shares have now been issued pursuant to the Placing with the remaining 4,583,332 New Shares to be issued conditional upon shareholder approvals at the Meeting.

In addition to the New Shares, the Company has issued an aggregate of 344,815 non-transferable warrants to the brokers who advised in connection with the Placing. Each warrant is exercisable for a period of 12 months with an exercise price of £0.24 per warrant. The warrants (and the underlying shares) are subject to a statutory hold period in Canada expiring on the date that is four months and one day from the issuance of the warrants.

Admission to trading on AIM and Total Voting Rights

Application has been made for the 18,424,163 New Shares, which will rank pari passu with the existing common shares of no par value each ("Common Shares") of the Company, to be admitted to trading on AIM ("Admission"). It is expected that Admission of 18,074,163 of the New Shares will become effective and dealings will commence at 8:00 a.m. on or around 17 August 2021, and Admission of the remaining 350,000 New Shares will become effective and dealings will commence at 8:00 a.m. on or around 18 August 2021.

Following the issue of these New Shares, the total issued share capital of the Company will consist of 153,949,884 Common Shares. The Company does not hold any Common Shares in Treasury. Therefore, the total current voting rights in the Company following Admission will be 153,949,884 and this figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

The New Shares will also be listed for trading on the TSX-V and will be subject to a statutory hold period in Canada expiring on the date that is four months and one day from issuance of the New Shares.

 

About Mkango

Mkango's corporate strategy is to develop new sustainable primary and secondary sources of neodymium, praseodymium, dysprosium and terbium to supply accelerating demand from electric vehicles, wind turbines and other clean technologies. This integrated Mine, Refine, Recycle strategy differentiates Mkango from its peers, uniquely positioning the Company in the rare earths sector.

Mkango is developing Songwe Hill in Malawi with a Feasibility Study targeted for completion in Q1 2022. Malawi is known as "The Warm Heart of Africa", a stable democracy with existing road, rail and power infrastructure, and new infrastructure developments underway.

In parallel, Mkango recently announced that Mkango and Grupa Azoty PULAWY, Poland's leading chemical company and the second largest manufacturer of nitrogen and compound fertilizers in the European Union, have agreed to work together towards development of a rare earth Separation Plant at Pulawy in Poland. The Separation Plant will process the purified mixed rare earth carbonate produced at Songwe.

Through its ownership of Maginito (www.maginito.com), Mkango is also developing green technology opportunities in the rare earths supply chain, encompassing neodymium (NdFeB) magnet recycling as well as innovative rare earth alloy, magnet, and separation technologies. Maginito holds a 25% interest in UK rare earth (NdFeB) magnet recycler, HyProMag (www.hypromag.com) with an option to increase its interest to 49%.

Mkango also has an extensive exploration portfolio in Malawi, including the Mchinji rutile discovery, for which assay results are pending, in addition to the Thambani uranium-tantalum-niobium-zircon project and Chimimbe nickel-cobalt project.

For more information, please visit www.mkango.ca.

Cautionary Note Regarding Forward-Looking Statements

This news release contains forward-looking statements (within the meaning of that term under applicable securities laws) with respect to Mkango, its business, the Plant and Songwe. Generally, forward looking statements can be identified by the use of words such as "plans", "expects" or "is expected to", "scheduled", "estimates" "intends", "anticipates", "believes", or variations of such words and phrases, or statements that certain actions, events or results "can", "may", "could", "would", "should", "might" or "will", occur or be achieved, or the negative connotations thereof. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. By their nature, forward-looking statements involve numerous assumptions, known and unknown risks and uncertainties, both general and specific, that contribute to the possibility that the predictions, forecasts, projections and other forward-looking statements will not occur, which may cause actual performance and results in future periods to differ materially from any estimates or projections of future performance or results expressed or implied by such forward-looking statements. Such factors and risks include, without limiting the foregoing, Shareholder approval of the Transaction and the investments by related parties, TSX-V approval of the Transaction and the Placing, settlement risk with respect to the Placing, governmental action relating to COVID-19, COVID-19 and other market effects on global demand and pricing for the metals and associated downstream products for which Mkango is exploring, researching and developing, factors relating the development of the Separation Plant, including the outcome and timing of the completion of the feasibility studies, cost overruns, complexities in building and operating the Separation Plant, changes in economics and government regulation, the positive results of a feasibility study on Songwe Hill and delays in obtaining financing or governmental approvals for, and the impact of environmental and other regulations relating to, Songwe Hill and the Separation Plant. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Additionally, the Company undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.

 

For further information on Mkango, please contact:

 

Mkango Resources Limited

William Dawes Alexander Lemon

Chief Executive Officer President

will@mkango.ca alex@mkango.ca 

Canada: +1 403 444 5979

 

www.mkango.ca

@MkangoResources

 

Blytheweigh

Financial Public Relations

Tim Blythe

UK: +44 20 7138 3204

 

SP Angel Corporate Finance LLP

Nominated Adviser and Joint Broker

Jeff Keating, Caroline Rowe

UK: +44 20 3470 0470

 

Alternative Resource Capital

Joint Broker

Alex Wood, Keith Dowsing

UK: +44 20 7186 9004/5

 

Shard Capital Partners LLP

Placing Agent

Damon Heath

UK: +44 20 7186 9952

 

Bacchus Capital Advisers

Strategic and Financial Adviser

Richard Allan Andrew Krelle

UK: +44 20 3848 1642 UK: +44 79 5636 2903

 

The TSX Venture Exchange has neither approved nor disapproved the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

This press release does not constitute an offer to sell or a solicitation of an offer to buy any equity or other securities of the Company in the United States. The securities of the Company will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold within the United States to, or for the account or benefit of, U.S. persons except in certain transactions exempt from the registration requirements of the U.S. Securities Act.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEFLFVFTAIVLIL
Date   Source Headline
18th May 20187:00 amRNSMKANGO SIGNS DEFINITIVE AGREEMENTS WITH TALAXIS
3rd May 20187:00 amRNSMKANGO PROVIDES UPDATE ON SONGWE
13th Apr 20187:00 amRNSAnnual Financial Report
1st Mar 20187:00 amRNSMKANGO ANNOUNCES EXERCISE OF WARRANTS
26th Jan 20183:00 pmRNSMKANGO ANNOUNCES EXERCISE OF WARRANTS
25th Jan 20187:00 amRNSMKANGO ANNOUNCES EXERCISE OF WARRANTS
24th Jan 20183:30 pmRNSMKANGO RECEIVES £6M INVESTMENT FROM TALAXIS
18th Jan 20184:10 pmRNSMKANGO ANNOUNCES SHAREHOLDER APPROVAL
12th Jan 20187:00 amRNSMKANGO ANNOUNCES EXERCISE OF WARRANTS
8th Jan 20183:01 pmRNSHolding(s) in Company
8th Jan 20182:05 pmRNSSecond Price Monitoring Extn
8th Jan 20182:00 pmRNSPrice Monitoring Extension
14th Dec 20177:00 amRNSMKANGO ANNOUNCES EXERCISE OF WARRANTS
11th Dec 20177:00 amRNSMKANGO RECEIVES CONDITIONAL TSX-V APPROVAL
29th Nov 20177:00 amRNSNickel Cobalt Exploration Licence Granted
28th Nov 20177:00 amRNS3rd Quarter Results
24th Nov 20177:00 amRNSExercise of Warrants
16th Nov 201711:05 amRNSSecond Price Monitoring Extn
16th Nov 201711:00 amRNSPrice Monitoring Extension
16th Nov 20179:00 amRNSPrice Monitoring Extension
16th Nov 20177:00 amRNSMkango enters into agreement with Talaxis
6th Nov 201710:20 amRNSHolding(s) in Company
3rd Nov 20173:04 pmRNSHolding(s) in Company
1st Nov 20171:30 pmRNSMKANGO GRANTS STOCK OPTIONS
1st Nov 20177:00 amRNSHolding(s) in Company
27th Oct 201711:20 amRNSHolding(s) in Company
27th Oct 201711:15 amRNSHolding(s) in Company
27th Oct 20179:29 amRNSHolding(s) in Company
26th Oct 20177:00 amRNSResult of Equity Issue
29th Sep 20177:00 amRNSMKANGO ADVANCES METALYSIS PROJECT & RAISES £500K
30th Aug 20177:00 amRNSMkango Releases 2nd Quarter Results
23rd Aug 20177:00 amRNSMkango renews Thambani Licence
25th May 20177:00 amRNS1st Quarter Results
24th May 20177:00 amRNSHigh grade Uranium, Tantalum, Niobium at Thambani
27th Apr 201710:55 amRNSHolding(s) in Company
12th Apr 20177:00 amRNSAnnual Financial Report
20th Mar 20177:00 amRNSMKANGO ANNOUNCES R&D PROGRAMME WITH METALYSIS
1st Mar 20177:00 amRNSMkango Resources Corporate Update
20th Feb 20172:30 pmRNSResults of Annual General Meeting
6th Feb 201710:49 amRNSHolding(s) in Company
2nd Feb 20177:00 amRNSMKANGO COMMENCES EXPLORATION ON URANIUM PROJECT
5th Jan 201710:33 amRNSHolding(s) in Company
5th Jan 201710:32 amRNSHolding(s) in Company
5th Jan 201710:30 amRNSHolding(s) in Company
5th Jan 201710:30 amRNSHolding(s) in Company
30th Dec 20167:00 amRNSReceives Regulatory Approval for Noble transaction
19th Dec 20167:00 amRNSMkango enters into Agreement with Noble
29th Nov 20167:00 amRNS3rd Quarter Results
18th Nov 20163:11 pmRNSHolding in Company
18th Oct 20167:00 amRNSMKANGO RENEWS PHALOMBE LICENCE

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.